NBP NovaBridge Biosciences
Pharmaceutical Preparations · Nasdaq · SEC CIK 1778016 · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY140.7%
TTM net income YoY44.0%
TTM EPS YoY44.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-11,395.1%
Net margin-32,868.5%
FCF margin-11,528.6%
EBITDA margin-11,319.9%
Returns
ROE-62.9%
ROA-43.3%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets34.2%
Debt / equity0.00x
Current ratio5.67x
Interest coverage-706.05x
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-28.1%
Payout ratio—
Capex / revenue25.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $632,000 | -$1.55M | $13.81M |
| Cost of revenue | — | — | — | $3.95M | $7.29M |
| Gross profit | — | — | — | -$5.50M | $6.53M |
| R&D expense | $62.91M | $21.77M | $21.45M | $22.55M | $190.34M |
| SG&A expense | $31.36M | $29.66M | $28.16M | $28.98M | $141.22M |
| Operating income | -$94.27M | -$51.43M | -$72.02M | -$53.08M | — |
| Interest expense | — | — | $102,000 | $1,000 | $0 |
| Pretax income | -$88.34M | -$49.70M | -$82.22M | -$141.10M | -$366.37M |
| Income tax | $0 | $0 | $0 | $103,000 | -$495,000 |
| Net income | -$46.27M | -$22.23M | -$207.73M | -$371.05M | -$365.87M |
| EBITDA | -$94.20M | -$51.16M | -$71.54M | -$52.88M | — |
| EPS (basic) | -0.21 | -0.12 | -1.09 | -1.96 | -2.09 |
| EPS (diluted) | -0.21 | -0.12 | -1.09 | -1.96 | -2.09 |
| Weighted avg. shares (diluted) | 220.26M | 186.73M | 191.42M | 189.79M | 174.71M |
| Balance sheet | |||||
| Cash & equivalents | $210.63M | $68.26M | $291.51M | $475.37M | $552.67M |
| Short-term investments | $210,000 | $105.14M | $20.22M | $34.13M | $118.19M |
| Receivables | — | — | — | $0 | $5.19M |
| Inventory | — | — | — | $0 | $4.27M |
| Current assets | $217.52M | $176.69M | $329.91M | $525.79M | $750.36M |
| PP&E, net | $140,000 | $201,000 | $1.78M | $8.82M | $7.17M |
| Goodwill | — | — | — | $23.57M | $25.51M |
| Intangibles | — | — | $16.64M | $17.24M | $18.78M |
| Total assets | $260.52M | $212.68M | $368.92M | $590.62M | $878.95M |
| Current liabilities | $26.89M | $8.45M | $58.14M | $109.92M | $97.92M |
| Short-term debt | — | — | $4.22M | $2.75M | — |
| Total liabilities | $29.58M | $11.52M | $126.34M | $168.73M | $163.45M |
| Shareholders' equity | $230.94M | $201.16M | $242.58M | $417.81M | $715.15M |
| Shares outstanding | 265.38M | 187.45M | 185.61M | 190.88M | 183.83M |
| Cash flow statement | |||||
| Operating cash flow | -$20.60M | -$52.67M | -$72.70M | -$49.58M | -$152.70M |
| Capital expenditure | $7,000 | $48,000 | $164,000 | $2.09M | $4.70M |
| Free cash flow | -$20.60M | -$52.72M | -$72.86M | -$51.67M | -$157.40M |
| Investing cash flow | $104.97M | -$136.01M | -$15.16M | -$5.18M | -$114.11M |
| Financing cash flow | $57.73M | -$335,000 | -$8.24M | $3.91M | $93.20M |
| Depreciation & amortization | $68,000 | $261,000 | $475,000 | $200,000 | $2.16M |
| Stock-based compensation | $5.97M | -$1.95M | $10.24M | $13.15M | $95.50M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.